Tilray (NASDAQ: TLRY) has announced the support of two additional clinical trials both in Australia and in Canada.
The first – a pilot study led by Murdoch Children’s Research Institute in Melbourne, to evaluate the feasibility and acceptability of a larger trial of medicinal cannabis as a form of treatment for reducing Severe Behavioural Problems in paediatric patients with Intellectual Disabilities.
The second – a study with McGill University Health Centre’s Division of Infectious Diseases and Chronic Viral Illness, to examine the effectiveness of medical cannabis on immune activation in people living with HIV.
For both these studies, Tilray is supplying the medication – a 1:1 oral solution for the first, and a two different CBD & THC strength capsules for the second.
Philippe Lucas, Tilray’s VP of Global Patient Research and Access said, “Tilray is at the forefront of clinical research in the medical cannabis field and we’re very proud to support two groundbreaking studies that have potential to identify more indications in which medical cannabis can benefit patients in-need.
“We are committed to advancing cannabinoid-based science to further understand the potential benefits of medical cannabis as a treatment option among these critical patient populations. There is a serious need for more clinical data in our field, and we are proud to support research like this around the world.”
These two trials add to an already broad clinical research involvement”
- Phase II/III Chemotherapy-Induced Nausea and Vomiting in partnership with USYD and the NSW Government.
- Phase II Dravet Syndrome in partnership with Toronto’s Hospital for Sick Children.
- Phase II PTSD for Canadian military veterans, law enforcement officers and sexual assault survivors in partnership with the University of British Columbia.
- Effects of medical cannabinoid use on driving safety in partnership with USYD.
- Safety, tolerability and efficacy of cannabinoids in children with severe epilepsy in partnership with the VIC Government.